|
Five Prime strikes deal with GSK for asthma drug
San Francisco Business Times The collaboration will give GlaxoSmithKline exclusive access to therapeutic drugs developed by Five Prime for refractory asthma and chronic obstructive pulmonary disease. The deal will allow Five Prime to receive up to $30 million over the next four … Five Prime Therapeutics Announces Second Strategic Alliance With GlaxoSmithKline |
View full post on asthma – Google News